Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors

NCT06077877 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06077877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06077877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 24, 2023
Completion date
June 30, 2026
Enrollment
42 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms